Astrazeneca Ab

Dizal (jiangsu) Pharmaceutical Co., Ltd.

James Francis McCabe

Robert Hugh Bradbury

Jason Grant Kettle

Michael James Waring

Alfred Arthur Rabow

Steven Christopher Glossop

Zoe Ann Cotter

Arshed Mahmood

Sameer Pralhad Kawatkar

Qibin Su

Melissa Vasbinder

Claudio Edmundo Chuaqui

Neil Patrick Grimster

Magnus K Nilsson

Jon James Winter-Holt

Richard Donald Woessner

Linette Ruston

Steven Swallow

Clifford David Jones

Richard Andrew Ward

Andrew Hornby Dobson

Mark Andrew Graham

Annika Birgitta Margareta Astrand

Laurent Francois Andre Hennequin

Carl-Johan Aurell

James Gair Ford

Lyn Powell

Gary Peter Tomkinson

Andrew Turner

Mark Purdie

Simon Mark Pointon

Philip O'Keefe

Jane Withnall

Anna Matilda Angelica Pettersen

Annika Astrand

Anne O'Kearney-McMullan

The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R, Rand n have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use as anti-proliferative and/or cell-killing agents.

[1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases

Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein

Compounds and methods for inhibiting JAK

The present disclosure relates to salts of compounds of Formula (I) prepared as a xinafoate (1-hydroxy-2-naphthoate) salt (Formula (Ia)), pharmaceutically acceptable compositions comprising same and methods of using the same. 

Salts of IJAK inhibitors and methods of using the same

[1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases

The present disclosure concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R, Rand Rhave any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cancer.

Chemical compounds

The invention concerns compounds of Formula (I) (Formula (I)) or pharmaceutically-acceptable salts thereof, wherein R, Rand n have any of the meanings defined herein before in the description; processes for their preparation, pharmaceutical compositions containing them and their use as anti-proliferative and/or cell-killing agents. 

The present invention relates to AZD2171 maleate salt, to particular crystalline forms of AZD2171 maleate salt, to processes for their preparation, to pharmaceutical compositions containing them as active ingredient, to their use in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans, and to their use in methods for the treatment of disease states associated with angiogenesis and/or increased vascular permeability.

Maleate salts of a quinazoline derivative useful as an antiangiogenic agent

The present invention relates to chemical processes useful in the manufacture of the compound 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline (the active entity within AZD0530), to intermediates useful in the manufacture of that compound and to processes for the manufacture of those intermediates. The invention also relates to particular crystalline forms of that compound such as a difumarate salt and a trihydrate and to pharmaceutical compositions containing such crystalline forms.

Crystalline forms of 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline

A novel crystalline form of 3-{[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-[(1-methylethyl)oxy]-N-1H-pyrazol-3-ylbenzamide is described in the specification. This compound is a glucokinase (GLK or GK) activator and useful as a pharmaceutical agent in the treatment or prevention of a disease or medical condition mediated through GLK, leading to a decreased glucose threshold for insulin secretion. Processes for the manufacture of the crystalline form, pharmaceutical compositions comprising the crystalline form and the use of the crystalline form in medical treatment are also described.

Crystalline compound

Growing community of inventors

Cheshire, United Kingdom

James Francis McCabe